ONCAlert | Upfront Therapy for mRCC

Bladder Cancer VIEW MORE >>

In an interview with Targeted Oncology, Nicholas J. Vogelzang, MD, FACP, FASCO, explained the need for updates to clinical trial criteria to make checkpoint inhibition more widely available to patients with metastatic bladder cancer.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.